Structural pharmacological studies on EGFR T790M/C797S

Biochemical and Biophysical Research Communications

Volumn 488, Issue 2, 2017, Pages 266-272

  Kong, Lu Lu ^a   Ma, Rui ^a   Yao, Ming Yu ^b   Yan, Xiao E ^a   Zhu, Su Jie ^a   Zhao, Peng ^a   Yun, Cai Hong ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Fengnan District Hospital   (China)

Author keywords

C797S; Drug resistance; EGFR; G 6976; T790M

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; EPIDERMAL GROWTH FACTOR RECEPTOR; CARBAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ARTICLE; COVALENT BOND; CRYSTAL STRUCTURE; ENZYME KINETICS; HUMAN; HYDROPHILICITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; GENETICS; METABOLISM; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

CARBAZOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85019384830     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2017.04.138     Document Type: Article

References (31)

1. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J. Clin. 65 (2015), 87–108.
2. Travis, W.D., Travis, L.B., Devesa, S.S., Lung cancer. Cancer 75 (1995), 191–202.
3. Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer. N. Engl. J. Med. 359 (2008), 1367–1380.
4. Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., Haber, D.A., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004), 2129–2139.
5. Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., Meyerson, M., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004), 1497–1500.
6. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., Mardis, E., Kupfer, D., Wilson, R., Kris, M., Varmus, H., EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 13306–13311.
7. Sharma, S.V., Bell, D.W., Settleman, J., Haber, D.A., Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7 (2007), 169–181.
8. Balak, M.N., Gong, Y., Riely, G.J., Somwar, R., Li, A.R., Zakowski, M.F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M.G., Ladanyi, M., Miller, V.A., Pao, W., Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12 (2006), 6494–6501.
9. Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., Mitsudomi, T., Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12 (2006), 5764–5769.
10. Zhou, W., Ercan, D., Chen, L., Yun, C.H., Li, D., Capelletti, M., Cortot, A.B., Chirieac, L., Iacob, R.E., Padera, R., Engen, J.R., Wong, K.K., Eck, M.J., Gray, N.S., Janne, P.A., Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462 (2009), 1070–1074.
11. Walter, A.O., Sjin, R.T., Haringsma, H.J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., Sheets, M., St Martin, T., Karp, R., van Kalken, D., Chaturvedi, P., Niu, D., Nacht, M., Petter, R.C., Westlin, W., Lin, K., Jaw-Tsai, S., Raponi, M., Van Dyke, T., Etter, J., Weaver, Z., Pao, W., Singh, J., Simmons, A.D., Harding, T.C., Allen, A., Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 3 (2013), 1404–1415.
12. Cross, D.A., Ashton, S.E., Ghiorghiu, S., Eberlein, C., Nebhan, C.A., Spitzler, P.J., Orme, J.P., Finlay, M.R., Ward, R.A., Mellor, M.J., Hughes, G., Rahi, A., Jacobs, V.N., Red Brewer, M., Ichihara, E., Sun, J., Jin, H., Ballard, P., Al-Kadhimi, K., Rowlinson, R., Klinowska, T., Richmond, G.H., Cantarini, M., Kim, D.W., Ranson, M.R., Pao, W., AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4 (2014), 1046–1061.
13. Janne, P.A., Yang, J.C., Kim, D.W., Planchard, D., Ohe, Y., Ramalingam, S.S., Ahn, M.J., Kim, S.W., Su, W.C., Horn, L., Haggstrom, D., Felip, E., Kim, J.H., Frewer, P., Cantarini, M., Brown, K.H., Dickinson, P.A., Ghiorghiu, S., Ranson, M., AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1689–1699.
14. Sequist, L.V., Soria, J.C., Goldman, J.W., Wakelee, H.A., Gadgeel, S.M., Varga, A., Papadimitrakopoulou, V., Solomon, B.J., Oxnard, G.R., Dziadziuszko, R., Aisner, D.L., Doebele, R.C., Galasso, C., Garon, E.B., Heist, R.S., Logan, J., Neal, J.W., Mendenhall, M.A., Nichols, S., Piotrowska, Z., Wozniak, A.J., Raponi, M., Karlovich, C.A., Jaw-Tsai, S., Isaacson, J., Despain, D., Matheny, S.L., Rolfe, L., Allen, A.R., Camidge, D.R., Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 1700–1709.
15. Greig, S.L., Osimertinib: first global approval. Drugs 76 (2016), 263–273.
16. Ercan, D., Choi, H.G., Yun, C.H., Capelletti, M., Xie, T., Eck, M.J., Gray, N.S., Janne, P.A., EGFR mutations and resistance to Irreversible pyrimidine based EGFR inhibitors. Clin. Cancer Res. 21 (2015), 3913–3923.
17. Thress, K.S., Paweletz, C.P., Felip, E., Cho, B.C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., Ercan, D., Matthews, S.E., Cantarini, M., Barrett, J.C., Janne, P.A., Oxnard, G.R., Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21 (2015), 560–562.
18. Lee, H.J., Schaefer, G., Heffron, T.P., Shao, L., Ye, X., Sideris, S., Malek, S., Chan, E., Merchant, M., La, H., Ubhayakar, S., Yauch, R.L., Pirazzoli, V., Politi, K., Settleman, J., Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov. 3 (2013), 168–181.
19. Hu, C., Wang, A., Wu, H., Qi, Z., Li, X., Yan, X.E., Chen, C., Yu, K., Zou, F., Wang, W., Wu, J., Liu, J., Wang, B., Wang, L., Ren, T., Zhang, S., Yun, C.H., Liu, Q., Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget 8 (2017), 18359–18372.
20. Minor, W., Cymborowski, M., Otwinowski, Z., Chruszcz, M., HKL-3000: the integration of data reduction and structure solution–from diffraction images to an initial model in minutes. Acta Crystallogr. D. Biol. Crystallogr. 62 (2006), 859–866.
21. McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C., Read, R.J., Phaser crystallographic software. J. Appl. Crystallogr. 40 (2007), 658–674.
22. Yun, C.H., Mengwasser, K.E., Toms, A.V., Woo, M.S., Greulich, H., Wong, K.K., Meyerson, M., Eck, M.J., The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 2070–2075.
23. Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., Read, R.J., Rice, L.M., Simonson, T., Warren, G.L., Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D. Biol. Crystallogr. 54 (1998), 905–921.
24. Emsley, P., Cowtan, K., Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60 (2004), 2126–2132.
25. Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W., McCoy, A.J., Moriarty, N.W., Oeffner, R., Read, R.J., Richardson, D.C., Richardson, J.S., Terwilliger, T.C., Zwart, P.H., PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66 (2010), 213–221.
26. Schuttelkopf, A.W., van Aalten, D.M., PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D. Biol. Crystallogr. 60 (2004), 1355–1363.
27. Yun, C.H., Boggon, T.J., Li, Y., Woo, M.S., Greulich, H., Meyerson, M., Eck, M.J., Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11 (2007), 217–227.
28. Stamos, J., Sliwkowski, M.X., Eigenbrot, C., Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277 (2002), 46265–46272.
29. Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., Adolf, G.R., Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343 (2012), 342–350.
30. Wu, H., Hu, C., Wang, A., Weisberg, E.L., Chen, Y., Yun, C.H., Wang, W., Liu, Y., Liu, X., Tian, B., Wang, J., Zhao, Z., Liang, Y., Li, B., Wang, L., Wang, B., Chen, C., Buhrlage, S.J., Qi, Z., Zou, F., Nonami, A., Li, Y., Fernandes, S.M., Adamia, S., Stone, R.M., Galinsky, I.A., Wang, X., Yang, G., Griffin, J.D., Brown, J.R., Eck, M.J., Liu, J., Gray, N.S., Liu, Q., Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia 30 (2016), 173–181.
31. Zhang, X., Gureasko, J., Shen, K., Cole, P.A., Kuriyan, J., An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006), 1137–1149.